A 62-year-old man from Delhi presents with a 3-year history of progressive tremor in his right hand, which worsens at rest and improves with intentional movement. On examination, he has a resting tremor (4–5 Hz), cogwheel rigidity in both upper limbs, and a shuffling gait with reduced arm swing. His Mini-Mental State Examination score is 28/30. He denies hallucinations or orthostatic symptoms. Which of the following medications is the most appropriate first-line agent for his motor symptoms?

Explanation

## Clinical Presentation Analysis This patient has **idiopathic Parkinson disease (IPD)** with classic features: - Resting tremor (4–5 Hz, unilateral onset progressing bilaterally) - Cogwheel rigidity in both upper limbs - Bradykinesia (shuffling gait, reduced arm swing) - Age 62 with moderate motor involvement - No significant cognitive impairment (MMSE 28/30) or autonomic dysfunction ## First-Line Therapy Selection **Key Point:** In a 62-year-old patient with **moderate motor symptoms** (cogwheel rigidity, gait dysfunction, resting tremor), **Levodopa with carbidopa** is the most appropriate first-line agent. Levodopa remains the gold standard for symptomatic control in Parkinson disease and is preferred in patients aged ≥60 years or those with functionally significant motor disability. **High-Yield:** Current international guidelines (MDS, AAN) and Indian consensus (NAMS, AIIMS) recommend: - **Levodopa/carbidopa** as first-line for older patients (≥60–65 years) or those with moderate-to-severe motor symptoms - **Dopamine agonists** (ropinirole, pramipexole) may be considered in younger patients (<60 years) with mild, tremor-dominant disease to delay motor complications - In patients ≥60 years, dopamine agonists carry a higher risk of neuropsychiatric side effects (hallucinations, impulse control disorders, excessive daytime somnolence) compared to levodopa ## Why Levodopa with Carbidopa? | Feature | Levodopa/Carbidopa | Dopamine Agonist (Ropinirole) | Selegiline | Benztropine | |---------|-------------------|-------------------------------|-----------|-------------| | **First-line in ≥60 yrs or moderate symptoms** | ✓ Yes | Preferred in younger/mild | No | No | | **Symptomatic efficacy** | Excellent | Moderate | Poor | Moderate (tremor only) | | **Neuropsychiatric safety in elderly** | Better | Higher risk (hallucinations) | Safe | **Avoid** (anticholinergic) | | **Motor complication risk** | Present (long-term) | Lower | Minimal | No | **Why not the other options?** - **Ropinirole (A):** Preferred in younger patients (<60 years) with mild/tremor-dominant disease; in a 62-year-old with moderate motor symptoms, levodopa is more appropriate and safer - **Selegiline monotherapy (A):** MAO-B inhibitor with modest symptomatic benefit; not adequate as sole therapy for moderate motor symptoms - **Benztropine (D):** Anticholinergic; rarely used due to cognitive and autonomic side effects, especially in patients >60 years; only marginally useful for tremor **Clinical Pearl:** Carbidopa is combined with levodopa to inhibit peripheral dopa-decarboxylase, reducing peripheral conversion of levodopa to dopamine, thereby decreasing nausea/vomiting and allowing more levodopa to cross the blood-brain barrier. The standard ratio is 4:1 (levodopa:carbidopa). *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Harrison's Principles of Internal Medicine, 21st ed.)*